These findings provide evidence that TP53 deficiency and TET2 loss cooperate to drive the development of AML and that the immunosuppressive microenvironment seen in such cases may be amenable to therapeutic blockade of TIGIT signaling. This evidence concerns the gene TET2 and acute myeloid leukemia.